{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:28:47Z","timestamp":1794450527686,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-03594-6","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T01:11:46Z","timestamp":1739581906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Yali","family":"Bo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"issue":"3","key":"3594_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cnur.2018.04.008","volume":"53","author":"RK Meier","year":"2018","unstructured":"Meier RK. Polycystic ovary syndrome. Nurs Clin N Am. 2018;53(3):407\u201320.","journal-title":"Nurs Clin N Am"},{"issue":"12","key":"3594_CR2","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841\u201355.","journal-title":"Hum Reprod"},{"issue":"4","key":"3594_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/humupd\/dmq001","volume":"16","author":"LJ Moran","year":"2010","unstructured":"Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347\u201363.","journal-title":"Hum Reprod Update"},{"issue":"12","key":"3594_CR4","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"3594_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","volume":"10","author":"AE Joham","year":"2022","unstructured":"Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3594_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","volume":"97","author":"BC Fauser","year":"2012","unstructured":"Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28\u2013e3825.","journal-title":"Fertil Steril"},{"key":"3594_CR7","doi-asserted-by":"crossref","unstructured":"Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;(2):Cd007506.","DOI":"10.1002\/14651858.CD007506.pub2"},{"issue":"11","key":"3594_CR8","first-page":"Cd003053","volume":"11","author":"LC Morley","year":"2017","unstructured":"Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017;11(11):Cd003053.","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"3594_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.21037\/atm.2019.07.27","volume":"7","author":"PD Montan","year":"2019","unstructured":"Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals Transl Med. 2019;7(16):393.","journal-title":"Annals Transl Med"},{"issue":"3","key":"3594_CR10","doi-asserted-by":"publisher","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","volume":"13","author":"H Ma","year":"2023","unstructured":"Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13(3):e061807.","journal-title":"BMJ Open"},{"key":"3594_CR11","doi-asserted-by":"crossref","unstructured":"Scheen AJ. GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy. Drugs. 2024.","DOI":"10.1007\/s40265-024-02090-9"},{"issue":"2","key":"3594_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","volume":"39","author":"Y Han","year":"2019","unstructured":"Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019;39(2):332\u201342.","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"3594_CR13","doi-asserted-by":"publisher","first-page":"e13704","DOI":"10.1111\/obr.13704","volume":"25","author":"A Goldberg","year":"2024","unstructured":"Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Reviews: Official J Int Association Study Obes. 2024;25(5):e13704.","journal-title":"Obes Reviews: Official J Int Association Study Obes"},{"issue":"2","key":"3594_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130\u20137.","journal-title":"Ann Intern Med"},{"issue":"7","key":"3594_CR15","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9(7):e99682.","journal-title":"PLoS One"},{"key":"3594_CR16","first-page":"n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n160.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"10","key":"3594_CR17","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.","journal-title":"PLoS One"},{"issue":"4","key":"3594_CR18","first-page":"205","volume":"15","author":"M Amiri","year":"2014","unstructured":"Amiri M, Golsorkhtabaramiri M, Esmaeilzadeh S, Ghofrani F, Bijani A, Ghorbani L, et al. Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese\/overweight PCOS women under hypocaloric diet. J Reprod Infertility. 2014;15(4):205\u201313.","journal-title":"J Reprod Infertility"},{"issue":"2","key":"3594_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/dom.14583","volume":"24","author":"M Cai","year":"2022","unstructured":"Cai M, Shao X, Xing F, Zhang Y, Gao X, Zeng Q, et al. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial. Diabetes Obes Metab. 2022;24(2):312\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"3594_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2265.2008.03309.x","volume":"70","author":"LW Cho","year":"2009","unstructured":"Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol. 2009;70(2):233\u20137.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"3594_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-2003-39056","volume":"35","author":"KH Chou","year":"2003","unstructured":"Chou KH, von Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Hormone and metabolic research. 2003;35(2):86\u201391.","journal-title":"Hormone and metabolic research"},{"issue":"7","key":"3594_CR22","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"3594_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/met.2017.0095","volume":"15","author":"S Ferjan","year":"2017","unstructured":"Ferjan S, Janez A, Jensterle M. Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study. Metab Syndr Relat Disord. 2017;15(10):515\u201320.","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"3594_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2018;20(1):215\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3594_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/09513590903215581","volume":"26","author":"C Fux Otta","year":"2010","unstructured":"Fux Otta C, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol Endocrinology: Official J Int Soc Gynecol Endocrinol. 2010;26(3):173\u20138.","journal-title":"Gynecol Endocrinology: Official J Int Soc Gynecol Endocrinol"},{"issue":"2","key":"3594_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","volume":"60","author":"A Gambineri","year":"2004","unstructured":"Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol. 2004;60(2):241\u20139.","journal-title":"Clin Endocrinol"},{"issue":"7","key":"3594_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10815-011-9564-2","volume":"28","author":"S Ghandi","year":"2011","unstructured":"Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet. 2011;28(7):591\u20136.","journal-title":"J Assist Reprod Genet"},{"issue":"10","key":"3594_CR28","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1210\/jc.2005-0615","volume":"90","author":"D Glintborg","year":"2005","unstructured":"Glintborg D, St\u00f8ving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(10):5605\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3594_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/cen.13968","volume":"90","author":"Z Javed","year":"2019","unstructured":"Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin Endocrinol. 2019;90(6):805\u201313.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"3594_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1210\/jc.2004-0176","volume":"90","author":"V Jayagopal","year":"2005","unstructured":"Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2005;90(2):729\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"3594_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108935","volume":"178","author":"M Jensterle","year":"2021","unstructured":"Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Jane\u017e A. Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study. Diabetes Res Clin Pract. 2021;178: 108935.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"3594_CR32","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3892\/etm.2016.3081","volume":"11","author":"M Jensterle","year":"2016","unstructured":"Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study. Experimental Therapeutic Med. 2016;11(4):1194\u2013200.","journal-title":"Experimental Therapeutic Med"},{"issue":"1","key":"3594_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12902-017-0155-9","volume":"17","author":"M Jensterle","year":"2017","unstructured":"Jensterle M, Kravos NA, Gori\u010dar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disorders. 2017;17(1):5.","journal-title":"BMC Endocr Disorders"},{"issue":"1","key":"3594_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03401383","volume":"14","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens Greece). 2015;14(1):81\u201390.","journal-title":"Hormones (Athens Greece)"},{"key":"3594_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","volume":"8","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015;8:32.","journal-title":"J Ovarian Res"},{"issue":"3","key":"3594_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"3594_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/0974-1208.147492","volume":"7","author":"P Kumar","year":"2014","unstructured":"Kumar P, Arora S. Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates. J Hum Reproductive Sci. 2014;7(4):255\u201361.","journal-title":"J Hum Reproductive Sci"},{"issue":"7","key":"3594_CR38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1471-0528.2006.00966.x","volume":"113","author":"J Lord","year":"2006","unstructured":"Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome\u2013a randomised, double-blind, placebo-controlled trial. BJOG: Int J Obstet Gynecol. 2006;113(7):817\u201324.","journal-title":"BJOG: Int J Obstet Gynecol"},{"issue":"4","key":"3594_CR39","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/humrep\/den454","volume":"24","author":"M Metwally","year":"2009","unstructured":"Metwally M, Amer S, Li TC, Ledger WL. An RCT of metformin versus orlistat for the management of obese anovulatory women. Hum Reprod (Oxford England). 2009;24(4):966\u201375.","journal-title":"Hum Reprod (Oxford England)"},{"issue":"1","key":"3594_CR40","first-page":"139","volume":"85","author":"P Moghetti","year":"2000","unstructured":"Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85(1):139\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3594_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12020-014-0426-4","volume":"49","author":"A Moini","year":"2015","unstructured":"Moini A, Kanani M, Kashani L, Hosseini R, Hosseini L. Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial. Endocrine. 2015;49(1):286\u20139.","journal-title":"Endocrine"},{"issue":"9","key":"3594_CR42","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/humrep\/dei104","volume":"20","author":"IA Penna","year":"2005","unstructured":"Penna IA, Canella PR, Reis RM, Silva de S\u00e1 MF, Ferriani RA. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod (Oxford England). 2005;20(9):2396\u2013401.","journal-title":"Hum Reprod (Oxford England)"},{"key":"3594_CR43","doi-asserted-by":"crossref","unstructured":"Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study.\u00a0Fertil Steril. 2007;87(1):202\u20136.","DOI":"10.1016\/j.fertnstert.2006.05.061"},{"issue":"3","key":"3594_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/07435800.2014.966385","volume":"40","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. 2015;40(3):133\u20138.","journal-title":"Endocr Res"},{"key":"3594_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fendo.2014.00140","volume":"5","author":"CB Rasmussen","year":"2014","unstructured":"Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol. 2014;5:140.","journal-title":"Front Endocrinol"},{"issue":"6","key":"3594_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"B Viollet","year":"2012","unstructured":"Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (London England: 1979). 2012;122(6):253\u201370.","journal-title":"Clin Sci (London England: 1979)"},{"issue":"6","key":"3594_CR47","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabol. 2013;17(6):819\u201337.","journal-title":"Cell Metabol"},{"issue":"Suppl 1","key":"3594_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"3594_CR49","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1172\/JCI610","volume":"101","author":"SA Beak","year":"1998","unstructured":"Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD, et al. Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Investig. 1998;101(6):1334\u201341.","journal-title":"J Clin Investig"},{"issue":"6","key":"3594_CR50","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J van Can","year":"2014","unstructured":"van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International journal of obesity (2005). 2014;38(6):784\u201393.","journal-title":"International journal of obesity (2005)"},{"issue":"6","key":"3594_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981\u20131030.","journal-title":"Endocr Rev"},{"issue":"26","key":"3594_CR52","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1056\/NEJM199806253382603","volume":"338","author":"JE Nestler","year":"1998","unstructured":"Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338(26):1876\u201380.","journal-title":"N Engl J Med"},{"issue":"6","key":"3594_CR53","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3390\/nu13061848","volume":"13","author":"V Calcaterra","year":"2021","unstructured":"Calcaterra V, Verduci E, Cena H, Magenes VC, Todisco CF, Tenuta E, et al. Polycystic ovary syndrome in insulin-resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility. Nutrients. 2021;13(6):1848.","journal-title":"Nutrients"},{"issue":"6","key":"3594_CR54","first-page":"774","volume":"18","author":"A Dunaif","year":"1997","unstructured":"Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774\u2013800.","journal-title":"Endocr Rev"},{"issue":"10","key":"3594_CR55","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/j.1471-0528.2006.00990.x","volume":"113","author":"R Pasquali","year":"2006","unstructured":"Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG: Int J Obstet Gynecol. 2006;113(10):1148\u201359.","journal-title":"BJOG: Int J Obstet Gynecol"},{"issue":"4","key":"3594_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000453370","volume":"105","author":"K Conde","year":"2017","unstructured":"Conde K, Fabelo C, Krause WC, Propst R, Goethel J, Fischer D, et al. Testosterone rapidly augments retrograde endocannabinoid signaling in proopiomelanocortin neurons to suppress glutamatergic input from steroidogenic factor 1 neurons via upregulation of diacylglycerol lipase-\u03b1. Neuroendocrinology. 2017;105(4):341\u201356.","journal-title":"Neuroendocrinology"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03594-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-03594-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03594-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T01:12:53Z","timestamp":1739581973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-025-03594-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3594"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-03594-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review and meta-analysis, ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not involve human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}